Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant radiochemotherapy plus QL1706 for locally advanced Siewert II gastroesophageal junction adenocarcinoma
ChiCTR2600134147Phase 2Recruiting
- Sponsor
- Anyang Cancer Hospital
- Start
- Oct 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706, oxaliplatin and tegafur-gimeracil-oteracil in gastroesophageal junction adenocarcinoma, sponsored by Anyang Cancer Hospital. Primary endpoint: Pathologic complete response rate. Started Oct 2025; status: recruiting.
02
Drugs
QL1706oxaliplatintegafur-gimeracil-oteracil
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600134147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134147.